ラジオイムノアッセイの世界市場：市場規模・シェア・動向分析 (製品別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

ラジオイムノアッセイ市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のラジオイムノアッセイの市場規模は、2025年から2030年にかけてCAGR 2.93％を記録し、2030年には17億9,000万米ドルに達する見込みです。

市場成長の原動力は、高感度かつ特異的な診断用途におけるRIAの重要な役割です。RIAは、より新しいイムノアッセイ技術の台頭にもかかわらず、微量濃度のホルモン、薬剤、腫瘍マーカー、感染性物質を検出するための主要なソリューションであり続けています。主要な市場促進要因は、世界中で慢性疾患や感染症が増加していることです。UNAIDSによると、2023年には世界で3,990万人近くがHIVに感染し、130万人が新たに感染しており、RIAのような正確で信頼性の高い検査手法に対する継続的なニーズが反映されています。さらに、甲状腺疾患や特定のがんの罹患率の増加により、精密な内分泌・腫瘍診断の需要が高まっています。

RIA技術や試薬の最近の進歩も市場成長に寄与しています。Medipan GmbHのような企業は、TSH、Tg、カルシトニン用のRIAキットの保存可能期間を延長し、検査室の効率を向上させています。さらに、2022年に発売された同社の合理化されたSELco TRAb 1-stepアッセイは、甲状腺抗体の検出における所要時間とワークフローの簡便性を改善しました。戦略的提携と買収は、市場の統合と革新をさらに際立たせています。例えば、DiaSorinによるLuminex Corporationの買収は、そのマルチプレックス検査能力を拡大し、RIAを含む特殊診断における地位を強化しました。さらに、DIAsource社がSvar Life Science社（旧Euro Diagnostica社）と締結したマイルストーン契約は、高度な免疫測定ソリューションの開発をサポートし、RIA技術の普及をさらに後押ししています。

ラジオイムノアッセイ市場は、臨床診断と研究の両方における関連性によっても形成されています。臨床現場、特に病院や診断研究所では、ホルモン測定やアレルギー検査にRIAが日常的に使用されているため、かなりの市場シェアを占めています。一方、生物医学的研究にRIAの高い特異性を利用する研究室が最も急成長を牽引しています。LabLogic Systemsのような先進的な分析装置や自動ガンマカウンターの導入は、RIAワークフローの近代化をサポートし、ハイスループット・アプリケーションへのアクセスを広げます。

ラボオンチップ（LOC）技術の進歩は、従来のラジオイムノアッセイ（RIA）に革命をもたらしました。マイクロ流体RIAプラットフォーム（μ-RIA）の開発により、分析時間が約5分と大幅に短縮され、試薬消費量も最小限に抑えられました。これらの改良は、長時間のインキュベーションや放射性廃棄物の発生など、これまでのRIAの限界に対処するものであり、臨床診断におけるこの技術の適用性を高めるものです。これらの開発は、放射性標識とラジオイムノアッセイ手法を改良し、画像診断と標的診断におけるより高い精度、効率、安全性を目指す協調的な努力を強調するものです。最近、2025年3月にアルバータ大学の研究者が、モノクローナル抗体パニツムマブと放射性同位元素銅-64を組み合わせた新しい分子イメージング検査を発表しました。パニツムマブは非小細胞肺がん細胞で一般的に過剰発現している上皮成長因子受容体（EGFR）を標的にします。銅-64で標識されると、この結合体は精密なPETイメージングを可能にし、肺がんの早期発見とモニタリングを容易にします。このハイブリッド・アプローチは、従来の生検に代わる非侵襲的な選択肢を提供し、タイムリーな介入によって患者の転帰を改善する可能性があります。

ラジオイムノアッセイ市場：分析概要

• 製品別では、2024年に試薬・キットが73.23%の収益シェアでリードしています。内分泌、腫瘍、感染症、自己免疫疾患検査における信頼性の高い診断ツールに対する需要の高まりが、検査室や病院全体でのRIA試薬・キットの消費を大幅に押し上げています。これらのキットには通常、放射性標識抗原または抗体（一般にヨウ素125を使用）、緩衝液、標準品、分離試薬が含まれます。これらのキットは感度と特異性が高いため、臨床検査室ではTSH、インスリン、コルチゾール、テストステロン、エストラジオールなどのホルモンを検出するのに不可欠です。例えば、PerkinElmerとDIAsource ImmunoAssaysは、甲状腺機能検査（TSHやカルシトニンなど）、不妊ホルモン、腫瘍マーカー用の幅広いRIAキットを提供しており、日常的なスクリーニングや特殊な診断をサポートしています。一方、分析装置は予測期間中に最も急成長するセグメントとなる見込みです。
• 2024年のラジオイムノアッセイ産業にを用途別に見ると、ルーチン検査や専門的な医療検査にRIA技術が広く使用されていることから、臨床診断が収益ベースで76.33％のシェアを占め、業界をリードしています。この優位性は主に、微量濃度の生物学的マーカーを検出する際のこの手法の卓越した感度と特異性に起因しており、正確な診断、疾患モニタリング、治療方針の決定に非常に貴重なものとなっています。予測期間中、研究分野が最も急成長する見込みです。
• 病院は2024年に32.54％の売上シェアで市場の最終用途セグメントをリードしましたが、これは病院の包括的な診断能力と、正確なバイオマーカー検出を必要とする疾病の有病率の増加によるものです。RIAの卓越した感度と特異性は、患者サンプル中の低濃度のホルモン、薬剤、その他の物質を正確に測定するために、病院環境において不可欠なものとなっています。さらに、病院での自動化された高度なRIAシステムの採用により、ワークフローが合理化され、納期が短縮され、結果の正確性が向上しています。
• ラジオイムノアッセイの世界市場は、2024年には北米が47.43％の売上シェアで支配的でした。成長の原動力は、高度な医療インフラの存在、活発な研究開発（R&D）活動、精密な診断ツールを必要とする慢性疾患の高い流行です。さらに、支援的な政策と償還の枠組みが、臨床診断におけるRIAの採用と統合を促進しています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 ラジオイムノアッセイ市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場機会分析
  • サプライチェーン分析
  • 流通チャネル
• ラジオイムノアッセイ市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
• 医療費償還の概要
• 価格分析

第4章 ラジオイムノアッセイ市場：製品別の推定・動向分析

• セグメントダッシュボード
• ラジオイムノアッセイ市場：変動分析、製品別（2024年・2030年）
• 分析装置
• 試薬・キット

第5章 ラジオイムノアッセイ市場：用途別の推定・動向分析

• セグメントダッシュボード
• ラジオイムノアッセイ市場：変動分析、用途別（2024年・2030年）
• 研究
• 臨床診断

第6章 ラジオイムノアッセイ市場：最終用途別の推定・動向分析

• セグメントダッシュボード
• ラジオイムノアッセイ市場：変動分析、最終用途別（2024年・2030年）
• 病院
• 臨床診断検査室
• 製薬業界
• その他

第7章 ラジオイムノアッセイ市場：地域別の推定・動向分析

• ラジオイムノアッセイの市場シェア：地域別（2024年・2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • デンマーク
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業分類
• 世界企業の市場シェア分析（2024年）
• 企業ヒートマップ分析
• 戦略マッピング
  • 拡大
  • 企業合併・買収 (M&A)
  • パートナーシップとコラボレーション
  • 新製品の発売
  • 研究開発
• 企業プロファイル
  • DIAsource
  • Tecan Trading AG
  • PerkinElmer
  • DRG International Inc.
  • Oxford BioSystems
  • DiaSorin SpA
  • Eurodiagnostico, SL
  • MP Biomedicals
  • Merck KGaA

List of Tables

• Table 1 List of abbreviation
• Table 2 North America radioimmunoassay market, by region, 2018 - 2030 (USD Million)
• Table 3 North America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 4 North America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 5 North America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S. radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S. radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 8 U.S. radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 9 Canada radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 10 Canada radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 11 Canada radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 12 Mexico radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 13 Mexico radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 14 Mexico radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 15 Europe radioimmunoassay market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 17 Europe radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 18 Europe radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 19 Germany radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 20 Germany radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 21 Germany radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 22 UK radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 23 UK radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 24 UK radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 25 France radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 26 France radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 27 France radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 28 Italy radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 29 Italy radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 30 Italy radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 31 Spain radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 32 Spain radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 33 Spain radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 34 Denmark radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 35 Denmark radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 36 Denmark radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 37 Sweden radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 38 Sweden radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 39 Sweden radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 40 Norway radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 41 Norway radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 42 Norway radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific radioimmunoassay market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 47 China radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 48 China radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 49 China radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 50 Japan radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 51 Japan radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 52 Japan radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 53 India radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 54 India radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 55 India radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 56 South Korea radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 57 South Korea radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 58 South Korea radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 59 Australia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 60 Australia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 61 Australia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 62 Thailand radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 63 Thailand radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 64 Thailand radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 65 Latin America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 66 Latin America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 67 Latin America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 68 Brazil radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 69 Brazil radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 70 Brazil radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 71 Argentina radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 72 Argentina radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 73 Argentina radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 74 MEA radioimmunoassay market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 76 MEA radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 77 MEA radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 78 South Africa radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 79 South Africa radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 80 South Africa radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 84 UAE radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 85 UAE radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 86 UAE radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
• Table 87 Kuwait radioimmunoassay market, by product, 2018 - 2030 (USD Million)
• Table 88 Kuwait radioimmunoassay market, by application, 2018 - 2030 (USD Million)
• Table 89 Kuwait radioimmunoassay market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Radioimmunoassay market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Parent market outlook, 2024
• Fig. 10 Radioimmunoassay market driver impact
• Fig. 11 Radioimmunoassay market restraint impact
• Fig. 12 Market entry strategy
• Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Radioimmunoassay market: Product outlook and key takeaways
• Fig. 16 Radioimmunoassay market: Products movement analysis
• Fig. 17 Analyzers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Reagents and kits market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Radioimmunoassay market: Application outlook and key takeaways
• Fig. 20 Radioimmunoassay market: Application movement analysis
• Fig. 21 Research market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Radioimmunoassay market: End use outlook and key takeaways
• Fig. 24 Radioimmunoassay market: End use movement analysis
• Fig. 25 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Clinical diagnostics laboratories market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Pharmaceutical industries market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Radioimmunoassay Market: Regional outlook and key takeaways
• Fig. 30 Radioimmunoassay market: Regional movement analysis
• Fig. 31 North America
• Fig. 32 North America. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 U.S. key country dynamics
• Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Canada key country dynamics
• Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Mexico key country dynamics
• Fig. 38 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Europe
• Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 UK key country dynamics
• Fig. 42 UK market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Germany key country dynamics
• Fig. 44 Germany market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Spain key country dynamics
• Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 France key country dynamics
• Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Italy key country dynamics
• Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Denmark key country dynamics
• Fig. 52 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Sweden key country dynamics
• Fig. 54 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Norway key country dynamics
• Fig. 56 Norway market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Asia Pacific
• Fig. 58 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Japan key country dynamics
• Fig. 60 Japan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 China key country dynamics
• Fig. 62 China. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 India key country dynamics
• Fig. 64 India. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 South Korea key country dynamics
• Fig. 66 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Thailand key country dynamics
• Fig. 68 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Australia key country dynamics
• Fig. 70 Australia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 71 Latin America
• Fig. 72 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 73 Brazil key country dynamics
• Fig. 74 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 75 Argentina key country dynamics
• Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 MEA
• Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 South Africa key country dynamics
• Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 UAE key country dynamics
• Fig. 82 UAE market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 Saudi Arabia key country dynamics
• Fig. 84 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Kuwait key country dynamics
• Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Radioimmunoassay Market Growth & Trends:

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

• The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
• The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
• The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
• North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
• 1.7. Details of primary research
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.1.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
    • 1.9.2.1. Approach 2: Volume price analysis
• 1.10. Research Scope and Assumptions
  • 1.10.1. List of Secondary Sources
  • 1.10.2. List of Primary Sources
  • 1.10.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
    • 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
    • 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
    • 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Presence of Ambiguous Regulatory Framework
    • 3.2.2.2. High Cost of RIA Equipment
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Supply Chain Analysis
  • 3.2.5. Distribution Channel
    • 3.2.5.1. Direct Sales
    • 3.2.5.2. Distributors Network
    • 3.2.5.3. E-commerce and Online Platforms
    • 3.2.5.4. Major Distributors
• 3.3. Radioimmunoassay Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Legal landscape
• 3.4. Reimbursement Overview
• 3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Analyzers
  • 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Reagents and Kits
  • 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Research
  • 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Clinical Diagnostics
  • 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Clinical Diagnostics Laboratories
  • 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical Industries
  • 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

• 7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.2.3. Competitive Insights
    • 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.3.3. Competitive Insights
    • 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.4.3. Competitive Insights
    • 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.2.3. Competitive Insights
    • 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.3.3. Competitive Insights
    • 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.4.3. Competitive Insights
    • 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.5.3. Competitive Insights
    • 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.6.3. Competitive Insights
    • 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Sweden
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.7.3. Competitive Insights
    • 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.8.3. Competitive Insights
    • 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.9.3. Competitive Insights
    • 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.5.3. Competitive Insights
    • 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.6.3. Competitive Insights
    • 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.7.3. Competitive Insights
    • 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Global Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
• 8.6. Company Profiles
  • 8.6.1. DIAsource
    • 8.6.1.1. Participant's Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Recent Developments
  • 8.6.2. Tecan Trading AG
    • 8.6.2.1. Participant's Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Recent Developments
  • 8.6.3. PerkinElmer
    • 8.6.3.1. Participant's Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Recent Developments
  • 8.6.4. DRG International Inc.
    • 8.6.4.1. Participant's Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Recent Developments
  • 8.6.5. Oxford BioSystems
    • 8.6.5.1. Participant's Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Recent Developments
  • 8.6.6. DiaSorin S.p.A.
    • 8.6.6.1. Participant's Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Recent Developments
  • 8.6.7. Eurodiagnostico, S.L.
    • 8.6.7.1. Participant's Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Recent Developments
  • 8.6.8. MP Biomedicals
    • 8.6.8.1. Participant's Overview
    • 8.6.8.2. Financial Performance
    • 8.6.8.3. Product Benchmarking
    • 8.6.8.4. Recent Developments
  • 8.6.9. Merck KGaA
    • 8.6.9.1. Participant's Overview
    • 8.6.9.2. Financial Performance
    • 8.6.9.3. Product Benchmarking
    • 8.6.9.4. Recent Developments